Pediatrix Medical Group, Inc. (NYSE:MD – Get Free Report) EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Pediatrix Medical Group Trading Down 3.2 %
NYSE MD opened at $14.74 on Friday. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $16.41. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The stock’s 50 day moving average price is $12.46 and its two-hundred day moving average price is $9.81.
Pediatrix Medical Group (NYSE:MD – Get Free Report) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.29 EPS. As a group, research analysts forecast that Pediatrix Medical Group, Inc. will post 1.25 earnings per share for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
Several equities research analysts have commented on the stock. StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Wednesday. Mizuho boosted their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Truist Financial raised their price objective on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Jefferies Financial Group boosted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, UBS Group raised their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $16.10.
View Our Latest Stock Report on Pediatrix Medical Group
Pediatrix Medical Group Company Profile
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
Read More
- Five stocks we like better than Pediatrix Medical Group
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cisco Systems Long-Term AI Play Turns a Corner: New Highs Likely
- What is a Death Cross in Stocks?
- Why Zscaler Stock Has Analysts So Excited
- 3 Tickers Leading a Meme Stock Revival
- Spotify Stock Surge: Why Investors Are Buying Despite High Prices
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.